- Harrow Health ( NASDAQ: HROW ) has announced the pricing of an underwritten registered offering of 2,376,426 shares of its common stock.
- Each share is being issued at $10.52 for aggregate gross proceeds of $25M.
- The eyecare pharmaceutical company expects to use the net proceeds from the sale of to fund a portion of the purchase price payable for a previously announced acquisition, with any remaining net proceeds available for general corporate purposes.
- The offering is expected to close on or about December 16, 2022.
- Elsewhere, the firm has agreed to acquire exclusive U.S. commercial rights to five FDA?approved ophthalmic products from the Novartis ( NVS ) group.
For further details see:
Harrow Health prices $25M stock offering